NightstaRx Ltd. is developing an adeno-associated viral vector-based gene therapy to treat choroideremia, a rare X-linked hereditary retinal dystrophy for which there are no disease-modifying treatments and no other disclosed clinical programs.

The company was spun out of the University of Oxford and its technology transfer company, Isis Innovation Ltd., in late January with a £12 million ($19.8 million) series A round led by Syncona Partners and an exclusive, worldwide license to IP from the university covering AAV-REP1.